Forte Biosciences, Inc. (FBRX)
NASDAQ
Healthcare
Biotechnology
$54.78
▼ -8.24%
Market Cap
$1.12B
Sector
Healthcare
Industry
Biotechnology
Beta
2.84
52-Wk Range
9.1-62.46
CEO
Paul A. Wagner
Country
US
Currency
USD
Forte Biosciences, Inc. is a U.S.-based biopharmaceutical company currently in its clinical development phase. The firm's key initiative involves advancing the FB-102 program, which is designed to tackle a variety of autoimmune conditions, notably vitiligo and alopecia areata. Their main offices are situated in Dallas, Texas.
Open full interactive analysis & DCF →